Recognitions, Patent Issuance, Financial Results, Upcoming Investor Conferences and Update on ClinicalTrial - Research Report on Stereotaxis, Immunomedics, Novadaq, Avanir, and Raptor Pharmaceuticals

News provided by

Oct 28, 2013, 09:00 ET

NEW YORK, October 28, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Stereotaxis Inc. (NASDAQ: STXS), Immunomedics Inc. (NASDAQ: IMMU), Novadaq Technologies Inc. (NASDAQ: NVDQ), Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR), and Raptor Pharmaceuticals Corp. (NASDAQ: RPTP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Stereotaxis Inc. Research Report

On October 23, 2013, Stereotaxis Inc. (Stereotaxis) announced that the Ministry of Health, Labor, and Welfare (MHLW) in Japan had classified its Niobe Magnetic Navigation System as a C2 medical device. According to Stereotaxis, the C2 classification recognizes the Niobe system as a new, distinctive technology with clinical benefits and is the highest of five reimbursement categories for medical devices in Japan. The Company reported that the MHLW has also approved reimbursement for two electrophysiology ablation catheters compatible with Niobe magnetic navigation with effect from October 1, 2013. Stereotaxis informed that the latest achievement marks an important step toward more permanent reimbursement coverage of the Niobe system in Japan. The Company stated that Japan's MHLW, will establish a more permanent "technical fee" for procedures using the Niobe system during its biennial review of insurance reimbursement pricing for C2 devices before April 1, 2014 and until then and with effect from October 1, 2013, MHLW has approved a temporary "technical fee" of 343,700 yen ( c.$3,500) per Niobe procedure. The Full Research Report on Stereotaxis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/b071_STXS]

Immunomedics Inc. Research Report

On October 22, 2013, Immunomedics Inc. (Immunomedics) announced the issuance of U.S. patent no. 8,562,988 to its subsidiary, IBC Pharmaceuticals, Inc. (IBC), for "Novel Strategies for Improved Cancer Vaccines." Immunomedics stated that the new patent concerns methods and compositions for forming anti-cancer vaccine complexes created with the Company's proprietary DOCK-AND-LOCK (DNL) method. The Company informed that the allowed claims cover the use of bispecific antibodies targeting CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, of immune cells, and CD20 to form a vaccine complex. Immunomedics added that the said patent will expire in March 2026. Cynthia L. Sullivan, President and CEO, Immunomedics, commented, "This is an important patent protecting a new vaccine technology targeting dendritic cells for blood cancer treatment. This method also has the potential of including the use of a cytokine, such as interleukin-2, interleukin-12, or gamma-interferon." The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/c20d_IMMU]

Novadaq Technologies Inc. Research Report

On October 22, 2013, Novadaq Technologies Inc. (Novadaq) announced its Q3 2013 results. The Company reported total revenues of $8.9 million, representing an increase of 48.6% YoY, primarily driven by continued adoption of SPY technology procedures and higher capital system sales. Net loss stood at $6.9 million or $0.14 per diluted share in Q3 2013, compared to $9.3 million or $ 0.23 per diluted share in Q3 2012. Dr. Arun Menawat, Novadaq's President and CEO, stated, "The most notable achievement for Novadaq in the third quarter was the sale of 31 PINPOINT, LUNA, and SPY Elite systems. We remain focused on building our direct sales team further and continuing clinical studies to drive adoption of our PINPOINT and LUNA systems." The Full Research Report on Novadaq Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/3a51_NVDQ]

Avanir Pharmaceuticals, Inc. Research Report

On October 22, 2013, Avanir Pharmaceuticals, Inc. (Avanir) announced the enrollment of the first patient in study AVR-133. According to Avanir, the study is a proof of concept, Phase II clinical trial investigating the use of AVP-923 for treating levodopa induced dyskinesia (LID) in patients with Parkinson's disease (PD). According to the company, the said study will enroll approximately 16 PD patients across three study centers in the US and Canada and will compare AVP-923 (45 mg of dextromethorphan / 10 mg of quinidine) with placebo for treatment of LID. Anthony E. Lang, MD, Professor and Director of the Division of Neurology and Chair for Parkinson's Disease Research at the University of Toronto, said, "Despite advances in PD therapeutics, many patients still suffer with poorly controlled dyskinesias, especially as they require higher doses of medications to increase dopamine levels. Dyskinesias can not only be disabling but may also limit the dose of effective medications that treat core symptoms of PD." Avanir informed that it expects to release top line data for the study in H2 2014. The Full Research Report on Avanir Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2ee8_AVNR]

Raptor Pharmaceuticals Corp. Research Report

On October 21, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceuticals) announced that it will release its Q3 2013 financial results after the market closes on Thursday, November 7, 2013. The Company informed that it will also host a conference call to discuss its financial results and provide a corporate update on the same day at 4:30 p.m. EST (1:30 p.m. PST). The Company stated that the live webcast of the conference call and replay of the same will be available through its Investor Relations website. The Full Research Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/a001_RPTP]

----

EDITOR NOTES:

This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
For any urgent concerns or inquiries, please contact us at [email protected].
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner